RETRACTED ARTICLE: Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level
Authors:
- 22 July 2014
- journal article
- retracted article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 74 (3) , 531-538
Abstract
Aplysin, a natural brominate compound from marine organisms, has been demonstrated to exhibit anti-tumor activity, mainly by inducing apoptosis and cell cycle arrest. However, its effect on glioma is still unknown. In this study, we evaluated the effects of aplysin on the malignant properties of glioma cells and its enhancing effect on temozolomide (TMZ) action against drug-resistant glioma cell lines. We employed several human glioma cell lines and primary glioma cells to address this issue with multidisciplinary approaches. The combined application of aplysin and TMZ significantly sensitizes glioma cells to TMZ action, compared with TMZ alone. miRNA profile analysis revealed that the abundance of miR-181, an important glioma tumor suppressors believed to enhance TMZ effect, was greatly elevated in aplysin-treated glioma cell lines. The aplysin-induced TMZ sensitivity is dependent on MEK1 in glioma cells. Overexpression of MEK1 was able to abolish the effect of aplysin on glioma cells. We found that aplysin can enhance the effect of TMZ on glioma cells by increasing miR-181 expression.Keywords
This publication has 11 references indexed in Scilit:
- Treating malignant glioma in Chinese patients: update on temozolomideOncoTargets and Therapy, 2014
- Protective effect of Aplysin on hepatic injury in ethanol-treated ratsFood and Chemical Toxicology, 2013
- Saponins: the Potential Chemotherapeutic Agents in Pursuing New Anti-glioblastoma DrugsMini-Reviews in Medicinal Chemistry, 2013
- miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1Cancer Chemotherapy and Pharmacology, 2013
- Pharmacotherapeutic Management of Pediatric GliomasPediatric Drugs, 2012
- Molecular mechanisms of temozolomide resistance in glioblastoma multiformeExpert Review of Anticancer Therapy, 2012
- The strategy for enhancing temozolomide against malignant gliomaFrontiers in Oncology, 2012
- The Role of Bcl-2 Family Proteins in Therapy Responses of Malignant Astrocytic Gliomas: Bcl2L12 and BeyondThe Scientific World Journal, 2012
- Clinical trial end points for high-grade glioma: the evolving landscapeNeuro-Oncology, 2011
- hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cellsBrain Research, 2008